The authors offer their thoughts on a strategy for purchasing drugs to treat Hepatitis C (HCV) patients in the U.S. criminal justice system. They discuss how failure to properly treat incarcerated individuals with HCV can lead to further medical complications, disease transmission, or death. To address the costs of drugs, the authors suggest that correctional institutes partner with 340B safety-net providers or state Medicaid programs.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados